Common Specifications for Class D In Vitro Diagnostic Medical Devices
On 5 of July of 2022, the European Commission published the implementing Regulation (EU) 2022/1107 of 4 July 2022 laying down common specifications for certain class D in vitro diagnostic medical devices in accordance with Regulation (EU) 2017/746.

For certain class D in vitro diagnostic medical devices, there are no harmonised standards to respond to some requirements of Annex I of Regulation (EU) 2017/746. However, there is a need to address public health concerns as they can pose significant risks for public health and patient safety. Therefore, it is appropriate to adopt common specifications for those devices in respect of those requirements.

The common technical specifications under the Directive 98/79/EC were set out in Commission Decision 2002/364/EC. Once the Regulation (EU) 2017/746 replaced the Directive 98/79/EC, some of those common technical specifications have to be updated to reflect the current state of the art.

Entry into force and date of application

Regulation (EU) 2022/1107:

  • Enters into force in 25 July 2022
  • Applies from 25 July 2024

Transitional provisions

To ensure a continuous high level of safety and performance of devices, as a transitional measure, it is presumed that devices in conformity with Decision 2002/364/EC are in conformity with the requirements for certain performance characteristics set out in Annex I of Regulation (EU) 2017/746 until 25 July 2024.

Devices that are not in conformity with the common technical specifications set out in Decision 2002/364/EC should adopt solutions to ensure an equivalent level of safety and performance.

Devices that are in conformity with the common specifications set out in Regulation (EU) 2022/1107 are presumed to be in conformity with the performance requirements referred in Annex I to Regulation (EU) 2017/746.

Which requirements of Annex I of Regulation (EU) 2017/746 are covered by the common specifications?

Regulation (EU) 2022/1107 lays down common specifications for certain class D in vitro diagnostic medical devices in respect to the following performance requirements set out in Annex I to Regulation (EU) 2017/746:

  • Section 9.1, points (a) and (b)
  • Section 9.3
  • Section 9.4, point (a)

List of annexes of Regulation (EU) 2022/1107

  • Annex I – general common specifications for devices covered by Annexes II to XIII
  • Annex II – common specifications for devices intended for detection of blood group antigens in the ABO, Rh, Kell, Duffy and Kidd blood group systems.
  • Annex III – common specifications for devices intended for detection or quantification of markers of human immunodeficiency virus (HIV) infection.
  • Annex IV – common specifications for devices intended for detection or quantification of markers of human T-cell lymphotropic virus (HTLV) infection.
  • Annex V – common specifications for devices intended for detection or quantification of markers of hepatitis C virus (HCV) infection.
  • Annex VI – common specifications for devices intended for detection or quantification of markers of hepatitis B virus (HBV) infection.
  • Annex VII – common specifications for devices intended for detection or quantification of markers of hepatitis D virus (HDV) infection.
  • Annex VIII – common specifications for devices intended for detection of markers of variant Creutzfeldt-Jakob disease (vCJD).
  • Annex IX – common specifications for devices intended for detection or quantification of markers of cytomegalovirus (CMV) infection.
  • Annex X – common specifications for devices intended for detection or quantification of markers of Epstein-Barr virus infection (EBV).
  • Annex XI – common specifications for devices intended for detection of markers of Treponema pallidum infection.
  • Annex XII – common specifications for devices intended for detection or quantification of markers of Trypanosoma cruzi infection.
  • Annex XIII – common specifications for devices intended for detection or quantification of markers of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

further
reading

news & updates

EU Ecolabel adoption and recognition are on the rise

The Ecolabel certification is a comprehensive program focused on fostering sustainable practices. It evaluates products based on life cycle assessments, where every phase of said life cycle must abide by strict standards to attain the Ecolabel certification. The overarching objective of this certification is minimizing environmental harm from production or consumption activities.

Read More »
news & updates

SCCS preliminary opinion on Citral sensitization endpoint

Ingredients: CITRAL

Date of publication: 27/03/2024

On March 27 2024, the Scientific Committee on Consumer Safety (SCCS) published the Preliminary Opinion on the safety of Citral in cosmetic products. The deadline for comments is set to June 2, 2024.

Read More »
cosmetic products

UK proposes ban of wet wipes containing plastic 

The UK has proposed, on April 24, 2024, a regulation titled The Environmental Protection (Wet Wipes Containing Plastic) (England) Regulations 2024, to the World Trade Organization (WTO). The regulation aims to eliminate the supply and sale of plastic-containing wet wipes, including cosmetic ones. The public can offer comments on the draft until June 23, 2024, with adoption expected in September of the same year.

Read More »
medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »